
Contributions
Abstract: PB2477
Type: Publication Only
Background
Recovery of hematopoiesis after autologous stem cell transplantation (AutoSCT) depends on the count of the harvested CD34+ cells. It is supposed that count and proliferative capacity of mobilized stem cells are influenced by the kind of previous therapy and variety of chemotherapy agents used in the mobilization regimen.
Aims
The aim of the study was to determine prognostic significance of premobilization lenalidomide apply and the sort of mobilizatrion regimen (cyclophosphomide or vinorelbine) on the number of CD34+ cells in the autotransplant of multiple myeloma (MM) patients.
Methods
We examined the data of autotransplant harvesting in 68 patients retrospectively. Mobilization regimens with vinorelbine 35 mg/m/2 (23 patients) and cyclophosphamide 3.0 g/m/2 (45 patients) were used. 21 patients (30.9%) were treated with lenalidomide previously. In the group of patients treated with lenalidomide 14 patients were mobilized with vinorelbine and 7 patients with cyclophospamide.
Results
Mobilization failure with the number of CD34+ cells less than 2x10/6/kg was fixed in 5 patients (7.4%). There was no any difference in CD34+ cells number in groups of patients according to the age and MM variant. We found the trend with decreasing of CD34+ cells number in patients treated with lenalidomide: 4.1x10/6/kg (0.27-23.29) vs 6.76x10/6/kg (0.58-29.13) in patients who were not treated with lenalidomide; p=0.066. There was significant difference in the count of CD34+ cells harvested after cyclophospomide plus G-CSF and vinorelbine plus G-CSF: 6.8x10/6/kg (0.53-29.13) vs 3.96x10/6/kg (0.27-9.66) accordingly; p=0.022.
Conclusion
We conclude that vinorelbine plus G-CSF is a mobilization regimen of choice for older patients who were not treated with lenalidomide aggressively in the premobilization period and for whom the single AutoSCT is planned.
Session topic: 23. Stem cell transplantation - Clinical
Abstract: PB2477
Type: Publication Only
Background
Recovery of hematopoiesis after autologous stem cell transplantation (AutoSCT) depends on the count of the harvested CD34+ cells. It is supposed that count and proliferative capacity of mobilized stem cells are influenced by the kind of previous therapy and variety of chemotherapy agents used in the mobilization regimen.
Aims
The aim of the study was to determine prognostic significance of premobilization lenalidomide apply and the sort of mobilizatrion regimen (cyclophosphomide or vinorelbine) on the number of CD34+ cells in the autotransplant of multiple myeloma (MM) patients.
Methods
We examined the data of autotransplant harvesting in 68 patients retrospectively. Mobilization regimens with vinorelbine 35 mg/m/2 (23 patients) and cyclophosphamide 3.0 g/m/2 (45 patients) were used. 21 patients (30.9%) were treated with lenalidomide previously. In the group of patients treated with lenalidomide 14 patients were mobilized with vinorelbine and 7 patients with cyclophospamide.
Results
Mobilization failure with the number of CD34+ cells less than 2x10/6/kg was fixed in 5 patients (7.4%). There was no any difference in CD34+ cells number in groups of patients according to the age and MM variant. We found the trend with decreasing of CD34+ cells number in patients treated with lenalidomide: 4.1x10/6/kg (0.27-23.29) vs 6.76x10/6/kg (0.58-29.13) in patients who were not treated with lenalidomide; p=0.066. There was significant difference in the count of CD34+ cells harvested after cyclophospomide plus G-CSF and vinorelbine plus G-CSF: 6.8x10/6/kg (0.53-29.13) vs 3.96x10/6/kg (0.27-9.66) accordingly; p=0.022.
Conclusion
We conclude that vinorelbine plus G-CSF is a mobilization regimen of choice for older patients who were not treated with lenalidomide aggressively in the premobilization period and for whom the single AutoSCT is planned.
Session topic: 23. Stem cell transplantation - Clinical